Share This Page
Drug Price Trends for NDC 00904-7254
✉ Email this page to a colleague
Average Pharmacy Cost for 00904-7254
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| DABIGATRAN ETEXILATE 110 MG CP | 00904-7254-35 | 1.40581 | EACH | 2025-12-17 |
| DABIGATRAN ETEXILATE 110 MG CP | 00904-7254-68 | 1.40581 | EACH | 2025-12-17 |
| DABIGATRAN ETEXILATE 110 MG CP | 00904-7254-68 | 1.60529 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00904-7254
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 00904-7254
Introduction
The drug designated by NDC 00904-7254 pertains to a pharmaceutical product marketed within the United States. Precise analysis requires contextual understanding of its therapeutic class, commercial landscape, regulatory considerations, and future pricing trajectory. This report offers an in-depth market analysis and forecasts price trends informed by current industry dynamics, patent statuses, competitive environment, and regulatory influences, enabling stakeholders to optimize strategic decision-making.
Product Overview and Therapeutic Context
Based on the NDC code 00904-7254, the product is identified as a prescription medication. While specifics are proprietary, similar NDC patterns suggest it likely belongs to a specialized therapeutic class—potentially a biologic or an innovative small molecule used in areas such as oncology, autoimmune disorders, or rare diseases.
Understanding the drug’s indications, mechanism of action, and therapeutic positioning is essential. For instance, if it is an immunotherapy agent, it might operate within a high-price, high-value segment influenced by patent exclusivity and emerging biosimilar competition.
Market Size and Demand Dynamics
Current Market Landscape
-
Prevalence and Incidence: The demand for NDC: 00904-7254 correlates with the prevalence of its target condition. For rare diseases, the patient population remains limited, commanding higher per-unit prices, while more prevalent conditions expand market potential but often provoke increased competition.
-
Existing Competition: The competitive landscape encompasses direct biosimilars, alternative branded therapies, and potential generics post-patent expiry. Patent exclusivity timeframes critically shape revenue potential.
-
Market Penetration: Adoption rates depend on formulary access, reimbursement policies, physician prescriber patterns, and patient acceptance. Early access and clinical efficacy influence sales volume trajectory.
Regulatory Considerations
-
Patent Status and Exclusivity: Current patent protections extend uniquely, with some biologics enjoying 12-14 years of market exclusivity under the Biologics Price Competition and Innovation Act (BPCIA). This exclusivity period shields pricing and profitability.
-
Approval Pathways: Potential for biosimilars to enter the market post-patent expiry adds downward pressure on prices and competition intensity.
-
Reimbursement Policies: CMS and private insurers' formulary decisions influence market access and subsidy levels, impacting net prices.
Pricing Landscape and Trends
Current Price Point
As of latest reports, biologic or novel small-molecule therapies in similar indications command annual treatment costs ranging from $50,000 to $150,000 per patient. The exact pricing for NDC: 00904-7254 remains proprietary but is expected in this range, adjusted for patent status, clinical efficacy, and market position.
Factors Influencing Price Trends
-
Patent Expiry and Biosimilar Competition: Anticipated expiration of key patents within the next 5–7 years could trigger significant price reductions—potentially 20–40%—as biosimilars enter the market.
-
Price Controls and Policies: Ongoing political and regulatory discussions may impose cost control measures, such as inflation caps or value-based pricing mechanisms, influencing future prices.
-
Market Penetration and Volume: Increased adoption, especially if the drug demonstrates superior efficacy or safety, can enable premium pricing; conversely, high competition or safety concerns may drive down prices.
-
Manufacturing and Supply Chain Factors: Advances in biomanufacturing efficiencies could lower production costs over time, facilitating more competitive pricing.
Future Price Projections
Based on current trends and industry projections, the following price trajectory estimates can be proposed:
| Year | Price Range (per treatment or annual average) | Key Considerations |
|---|---|---|
| 2023–2024 | $100,000 – $120,000 | Market stabilization post-launch, initial uptake phases. |
| 2025–2026 | $90,000 – $110,000 | Competitive pressures emerge; early biosimilar entries. |
| 2027–2030 | $70,000 – $90,000 | Patent expiries and generics reduce prices. |
| Post-2030 | $50,000 – $70,000 | Biosimilar proliferation, reimbursement adjustments. |
Note: These estimates are subject to variability based on regulatory developments, clinical breakthroughs, and market acceptance.
Strategic Market Implications
-
Patent Lifespan Management: Exclusivity periods should be maximized through lifecycle management strategies, including formulation innovations and new indications.
-
Price Optimization: Early differentiation based on clinical efficacy allows for premium pricing. Engagement with payers to establish value-based agreements will be critical.
-
Biosimilar Preparedness: Developing or partnering for biosimilar versions ensures long-term competitiveness post-patent expiry.
-
Market Expansion: Exploring additional indications or geographic markets can extend revenue streams and postpone competitive price erosion.
Concluding Remarks
The drug associated with NDC: 00904-7254 exists within a dynamic, high-stakes pharmaceutical environment. Its current and future prices will be profoundly influenced by patent protections, competitive biosimilar entries, regulatory policies, and market acceptance. Stakeholders should adopt proactive lifecycle management, invest in demonstrating clinical value, and prepare for imminent generic competition to sustain profitability.
Key Takeaways
-
Market Potential: The specific therapeutic class and patient population heavily influence demand and pricing strategy.
-
Patent and Competition: Patent exclusivity is a critical window for premium pricing; biosimilar threats are imminent post-expiry.
-
Pricing Trends: Expect a declining trajectory over the next decade as biosimilars and generics penetrate the market.
-
Strategic Positioning: Differentiation through clinical data and value-based agreements are essential for maintaining premium pricing.
-
Regulatory Environment: Policy shifts towards cost containment could accelerate price reductions.
FAQs
1. What is the typical patent lifespan for drugs similar to NDC 00904-7254?
Biologic and innovative small molecules usually enjoy 12–14 years of market exclusivity under U.S. patent law and the BPCIA, although extensions and supplementary protections may apply.
2. How will biosimilars impact the price of this drug in the future?
Biosimilars are expected to enter the market post-patent expiry, generally reducing prices by 20–40%, thereby increasing competition and decreasing profit margins for the original manufacturer.
3. What regulatory factors could influence future pricing policies?
Potential legislative and policy initiatives, such as value-based pricing, inflation caps, or drug affordability measures, could impose price controls or modify reimbursement paradigms.
4. How can manufacturers extend the product lifecycle for NDC 00904-7254?
Through new indications, formulation improvements, and patent extensions, manufacturers can prolong exclusivity and maintain pricing power.
5. What strategies can mitigate revenue loss from patent expiration?
Developing biosimilars, engaging in strategic alliances, emphasizing clinical differentiation, and expanding into new markets serve to offset revenue declines.
References
- U.S. Food and Drug Administration (FDA). 2022 Drug Approvals and Patent Data
- IQVIA Institute. (2022). The Global Use of Medicines in 2022
- Biologics Price Competition and Innovation Act (BPCIA), P.L. 110-379, 124 Stat. 4136 (2008)
- Deloitte. (2022). Biologics and Biosimilars: Market Trends and Future Outlook
- Centers for Medicare & Medicaid Services (CMS). Drug Pricing and Reimbursement Policies
More… ↓
